These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30766446)

  • 21. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
    Mo C; Renoir T; Hannan AJ
    Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid activation and hepatic recruitment of innate-like regulatory B cells after invariant NKT cell stimulation in mice.
    Almishri W; Deans J; Swain MG
    J Hepatol; 2015 Oct; 63(4):943-51. PubMed ID: 26095178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of murine invariant NKT cells promotes susceptibility to candidiasis by IL-10 induced modulation of phagocyte antifungal activity.
    Haraguchi N; Kikuchi N; Morishima Y; Matsuyama M; Sakurai H; Shibuya A; Shibuya K; Taniguchi M; Ishii Y
    Eur J Immunol; 2016 Jul; 46(7):1691-703. PubMed ID: 27151377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated Activation of Lung Invariant NKT Cells Results in Chronic Obstructive Pulmonary Disease-Like Symptoms.
    Tsao CC; Tsao PN; Chen YG; Chuang YH
    PLoS One; 2016; 11(1):e0147710. PubMed ID: 26811900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of marginal zone B lymphocytes in invariant NKT cell activation.
    Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
    J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
    Glynn D; Reim K; Brose N; Morton AJ
    Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
    Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
    Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
    Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
    Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
    Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
    J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation or anergy: NKT cells are stunned by alpha-galactosylceramide.
    Sullivan BA; Kronenberg M
    J Clin Invest; 2005 Sep; 115(9):2328-9. PubMed ID: 16138189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntington's disease.
    Denny CA; Desplats PA; Thomas EA; Seyfried TN
    J Neurochem; 2010 Nov; 115(3):748-58. PubMed ID: 20731757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD; Johnson GV
    J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Solubilization of α-galactosylceramide in aqueous medium: Impact on Natural Killer T cell activation and antitumor responses.
    Macho-Fernandez E; Chekkat N; Ehret C; Thomann JS; De Giorgi M; Spanedda MV; Bourel-Bonnet L; Betbeder D; Heurtault B; Faveeuw C; Fournel S; Frisch B; Trottein F
    Int J Pharm; 2017 Sep; 530(1-2):354-363. PubMed ID: 28743554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CpG oligonucleotide-mediated co-stimulation of mouse invariant natural killer T cells negatively regulates their activation status.
    Kulkarni RR; Villanueva AI; Read LR; Brisbin JT; Bhaumik SK; LaMarre J; Murali-Krishna K; Sharif S
    Cell Tissue Res; 2017 Sep; 369(3):541-554. PubMed ID: 28550425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of signal-transducing adaptor protein-1 attenuates experimental autoimmune hepatitis via down-regulating activation and homeostasis of invariant natural killer T cells.
    Kashiwakura JI; Saitoh K; Ihara T; Sasaki Y; Kagohashi K; Enohara S; Morioka Y; Watarai H; Muromoto R; Kitai Y; Iwabuchi K; Oritani K; Matsuda T
    PLoS One; 2020; 15(11):e0241440. PubMed ID: 33175848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cell-type specific CD1d expression program modulates invariant NKT cell development and function.
    Zimmer MI; Colmone A; Felio K; Xu H; Ma A; Wang CR
    J Immunol; 2006 Feb; 176(3):1421-30. PubMed ID: 16424169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered invariant natural killer T cell subsets and its functions in patients with oral squamous cell carcinoma.
    Singh AK; Shukla NK; Das SN
    Scand J Immunol; 2013 Nov; 78(5):468-77. PubMed ID: 23980793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
    Hickey MA; Reynolds GP; Morton AJ
    J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.